EGFR and gastric cancer: Although the mechanism is not elucidated in GC, loss of NF1 has been associated with resistance to EGFR TKIs in lung adenocarcinomas and resistance to BRAF inhibitor in melanoma by increasing MAPK and/or PI3K signaling via negatively regulating Ras [44, 45].